Summary
Cencora, Inc. (formerly AmerisourceBergen Corporation) reported a significant increase in revenue for the fiscal year ending September 30, 2023, driven primarily by its U.S. Healthcare Solutions segment. This growth was fueled by increased unit volume, particularly in diabetes and weight loss medications (GLP-1 class), and specialty products. The company also saw a notable rise in gross profit, supported by increased sales, gains from antitrust litigation settlements, and expansion in its International Healthcare Solutions segment, including the acquisition of PharmaLex. However, operating expenses also rose, influenced by integration and rebranding costs associated with the company's name change. Despite these revenue and gross profit increases, the company's net income saw a slight decrease year-over-year. This was partly due to higher operating expenses, increased amortization from recent acquisitions, and the absence of a prior year goodwill impairment credit. Cencora continues to navigate a complex regulatory environment and manage the ongoing financial impact of opioid litigation, for which a substantial liability remains. The company also repurchased a significant amount of its own stock and continued to pay dividends, signaling a commitment to shareholder returns.
Financial Highlights
56 data points| Revenue | $262.17B |
| Cost of Revenue | $253.21B |
| Gross Profit | $8.96B |
| SG&A Expenses | $5.31B |
| Operating Expenses | $5.72B |
| Operating Income | $2.34B |
| Net Income | $1.75B |
| EPS (Basic) | $8.62 |
| EPS (Diluted) | $8.53 |
| Shares Outstanding (Basic) | 202.51M |
| Shares Outstanding (Diluted) | 204.59M |
Key Highlights
- 1Revenue increased by 9.9% to $262.2 billion, driven by a 10.7% rise in U.S. Healthcare Solutions revenue, boosted by strong sales of GLP-1 products and specialty pharmaceuticals.
- 2Gross profit grew by 8.0% to $9.0 billion, benefiting from increased sales, gains from antitrust litigation settlements, and contributions from the PharmaLex acquisition.
- 3Operating expenses increased by 11.6%, primarily due to higher distribution, selling, administrative costs, amortization, and restructuring expenses.
- 4The company acquired PharmaLex for $1.473 billion, strengthening its specialized services for the life sciences industry, and invested $718.4 million in a joint venture for OneOncology.
- 5Cencora's U.S. Healthcare Solutions segment's operating income increased by 5.7%, while the International Healthcare Solutions segment's operating income saw a 2.0% decrease, largely due to unfavorable foreign currency exchange rates.
- 6The company maintained a strong balance sheet with $2.59 billion in cash and cash equivalents and approximately $4.15 billion in additional availability under its credit facilities.
- 7Cencora repurchased $1.18 billion of its common stock during the fiscal year and increased its quarterly dividend by 5%.